DID YOU KNOW?


First opened to the public in 1844, Berlin Zoo is home to more than 15,000 animals representing around 1,400 species.

Situated in beautifully landscaped gardens, just one of this important zoo’s big stars is Knut. Born on Dec. 5, 2006 Knut was the first polar bear to be born at the zoo in over 30 years.



Photo: © Zoo Berlin, Peter Griesbach
 

ECCO 15 - ESMO 34
Congress Secretariat Avenue E. Mounier 83
B-1200 Brussels
Belgium
Tel:  +32 2 775 02 01
Fax: +32 2 775 02 45

Email: berlin09@ecco-org.eu
www.ecco-org.eu
ECCO 15 and 34th ESMO Multidisciplinary Congress
Berlin, 20 - 24 September 2009
This month’s ECCO 15 - ESMO 34 Congress Update Service brings you a snapshot of new insight, data and programme highlights, celebrates the current Call for Late Breaking Abstracts and connects you with ECCO 15 - ESMO 34 Roundtable TV!

Date for the diary: regular rate registration closes 03 August 2009. To benefit from specially reduced rates register to attend today!

Programme Highlights

The pick of Programme Highlights for this issue include:

New Insight & Data

Presidential Sessions

The Best of 2009 Session

CME Accreditation - claim your points 

Late Breaking Abstracts

The next few days represent the final chance to submit your data and make the headlines at ECCO 15 - ESMO 34!

Late-Breaking Abstract Submission will close 05 August 2009.

Roundtable TV

Previewing ECCO 15 - ESMO 34 highlights, headlines & hot topics!

We invite you to enjoy roundtable sessions with ECCO President and Congress Chair, the Executive Scientific Programme Committee, some of the Track Chairs and other invited guests.

More > More > More >
REGISTER NOW >    

Programme Highlights

New Insight & Data

Presidential Sessions

The Best of 2009 Session

CME Accreditation - claim your points

  • New Insight & Data

    Our dedicated efforts aimed at capturing some of the best European as well as international data to be showcased and make the headlines for the first time at ECCO 15 – ESMO 34 have been rewarded!

    We have consequently received a large amount of completely new data that will stimulate the very best discussions and ideas throughout the Congress. The Scientific Programme Committee have selected the most potentially impacting studies as oral presentations.

    To give you a mere snapshot of what we can look forward to in Berlin, here are a few of the many highlights in store:

    Breast Cancer:

     

    		  

    MoniCa - A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer (GBG39)
    Speaker:   M. Kaufmann (Germany)
         

    Colorectal Cancer:

    		 

    Aspirin prevents cancer in Lynch syndrome

    Speaker:

    		  J. Burn (UK)
         

     

    		  

    Late toxicity after preoperative (chemo)radiotherapy in non-resectable rectal cancer - results from a randomized phase III study

    Speaker:

    		  M. Braendengen (Norway)
         

     

    		  

    Calcium and magnesium (Ca/Mg) infusions to reduce oxaliplatin-induced neurotoxicity and outcome in advanced colorectal
    cancer (ACC) patients (pts) treated with oxaliplatin- and cetuximab-based therapy

    Speaker:

    		  J. Tol (The Netherlands)
         

    Lung Cancer:

    		 

    Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

    Speaker:

    		  

    J. Vansteenkiste (Belgium)
         
       

    A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405

    Speaker:

    		 

    J. Tsurutani (Japan)
         

    Prostate Cancer:

    		 

    Effect of baseline characteristics on prostate cancer rates and risk reduction in the REduction by DUtasteride of prostate Cancer Events REDUCE) trial
    Speaker:   M. Marberger (Austria)

     

    		  

     

    Sarcoma:

    		 

    A Phase II study of cediranib in patients with metastatic gastrointestinal stromal tumours (GIST) and metastatic soft tissue sarcoma (STS) (including alveolar soft part sarcoma [ASPS])

    Speaker:

    		 

    K. Gardner (United Kingdom)
         
       

    Eribulin mesylate (E7389) in patients with leiomyosarcoma (LMS) and other (OTH) subtypes of soft tissue sarcoma (STS): a Phase II study from the European Organisation for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC 62052)

    Speaker:

    		  P. Schöffski (Belgium)

  • Presidential Sessions

ECCO 15 – ESMO 34 Presidential Sessions are certainly not to be missed!

Kicking off with Presidential Session 1*, Monday 21 September 2009, 13:15 – 16:00, Co-Chairs A. M. M. Eggermont (The Netherlands) and J. Celis (Denmark) will lead the must-have conversation at this special Oncopolicy session:

The Unified Approach: Meeting the Cancer Challenges in the Next Decade

Presidential Sessions II, III and IV will showcase latest breaking and best abstracts as well as a series of prestigious Award Lectures (recipients of which will be announced next month!).

Avoid missing out by adding the following sessions and highlights to your ECCO 15 - ESMO 34 list of must-attends:

Presidential Session II *

Tuesday 22 September 2009, 12:30 – 14:30

Highlights: Hamilton - Fairley Award Lecture, ECCO – Pezcoller Award Lecture, late breaking and best abstracts.

Presidential Session III *

Wednesday 23 September 2009, 12:30 – 14:30

Highlights: ECCO Clinical Research Award Lecture, late breaking and best abstracts.

Presidential Session IV *

Thursday 24 September 2009, 09:00 – 11: 00

Highlights: Late breaking and best abstracts.

Presidential Session V - click here for more information

Thursday 24 September 2009, 12:30 – 14:30

* Coming soon: in the August edition of your ECCO 15 – ESMO 34 Congress Update Service Presidential Session highlights, award winners and expected headlines revealed!

  • The Best of 2009 Session

The Best of 2009 during Presidential Session V (Closing Session), Thursday 24 September 2009, 12:30 – 14:30

The Best of 2009 will showcase the practice changing data that made the headlines at other major meetings throughout the course of 2009.

Renowned speakers will join us in Berlin to present their ground breaking data once more, followed by specially selected discussants who will put the key findings into the European context.

Session highlights will include:

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP-1) Inhibitor in combination with gemcitabine/carboplation (G/C) in patients with Metastatic triple-negative breast cancer (TBNC): Results of a randomised phase II trial

Speaker:

  To be confirmed

Discussant:

 

S. B. Kaye (United Kingdom)

A Phase III study comparing concurrent gemcitabine(Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix

Speaker:

 

A. Duenas-Gonzalez (Mexico)

Discussant:

J. B. Vermorken (Belgium)

Trastuzumab added to standard chemotherapy (CT) as first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC): efficacy and safety results from the Phase III ToGA trial

Speaker:

 

E. Van Cutsem (Belgium)

Discussant:

  

A. Cervantes (Spain)

First results of a phase III multicenter randomised controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer

Speaker:

 

To be confirmed

Discussant:

 

M. Baumann (Germany)

Ulceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patients

Speaker:

  A. M. M. Eggermont (The Netherlands)

Discussant:

  To be confirmed

Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF- 02341066

Speaker:

  E. L. Kwak (USA)

Discussant:

  To be confirmed
 

  • CME Accreditation - claim your points

We are pleased to announce that the Accreditation Council of Oncology in Europe (ACOE) has appraised and approved the joint ECCO 15 - 34th ESMO Multidisciplinary Congress in acknowledgement of the quality of the scientific programme and its educational value, and is designated for a maximum of 21 European CME Credits (ECMECs).

ACOE credits have been endorsed by the European Accreditation Council for Continuing Medical Education (EACCME) - a body of the European Union of Medical Specialists (UEMS). ECMECs will be recognised within the different Members States which have agreed to participate in this European system as well as by the American Medical Association (AMA) as AMA Pra Category 1 Credits.

This conference operates an honour system. Each medical specialist should claim only those hours of credit that he/ she actually spent during the educational activity.

For further information or any queries please contact Nicola Pellegrino via email: accreditation@acoe.be

  • Call for Late-Breaking Abstracts

As a reflection of the European cancer community’s desire to showcase latest data and make the headlines, we have received a large amount of completely new and exciting data that will naturally stimulate the very best discussions and ideas throughout the Congress.

To capture even more abstracts with ground-breaking and practice changing data we remind you that Late-Breaking Abstract Submission is now open until 05 August 2009.

Examples of suitable late-breaking abstracts include: the results of a practice-changing prospective Phase III clinical trial, a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, or the demonstration of novel cancer biology with therapeutic implications.

To view our late-breaking abstract submission policy and regulations click here.

We look forward to receiving your breaking data and to welcoming you to Berlin for the premier European cancer meeting: ECCO 15 - ESMO 34, 20 - 24 September 2009.

To help attract the best abstracts describing new ideas and practice changing data from early clinical trials to muliticentre Phase III trials and to ensure maximum exposure for top quality and late-breaking abstracts, we have significantly increased both proffered paper slots and Presidential Sessions.

Click here to discover which of the Presidential Sessions will be showcasing the best abstracts and late breaking data!

Roundtable TV

In anticipation of the many highlights in store at the forthcoming ECCO 15 - ESMO 34 Congress, Berlin 20 - 24 September 2009, we invite you to sit back and enjoy our Roundtable TV series!

Discussants:

Alexander M. M. Eggermont (NL), President of ECCO, Congress Chair and Oncopolicy Track Co-Chair 

Kathy Oliver (UK), Co-Director of the International Brain Tumour Alliance

Maciej Krzakowksi (PL), The Maria Sklodowska-Curie Institute of Oncology

Paolo Casali (IT), ESMO Executive Committee Member

Discussants:

Fatima Cardoso (BE), Co-Chair, Breast Cancer – Advanced Disease Track

Rafael Rosell (ES), Chair, Lung Cancer Track

Josep Tabernero (ES), Co-Chair, Gastrointestinal Malignances Track – Colorectal and Non Colorectal Cancer

Thomas Wiegel (DE), Co-Chair, Genitourinary Malignancies Track – Prostate Cancer 

Discussants:

Alexander M.M. Eggermont (NL)

José Baselga (ES)

Chris J. Twelves (UK)

Fortunato Ciardiello (IT)  

Click here to access the different programme links and listen to conversation with some of the Track Chairs, discover the key Oncopolicy topics up for discussion and hear from the ECCO 15 - ESMO 34 Executive Scientific Programme Committee.
DISCLAIMER
You have been sent this email because you have attended or expressed an interest
in an ECCO event in the past. If you do not wish to continue to receive this special Update Service, please forward this message to info@ecco-org.eu with the word REMOVE in the subject field.